" class="no-js "lang="en-US"> Corbus Pharmaceuticals - Medtech Alert
Sunday, October 01, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Corbus Pharmaceuticals | Pharmtech Focus

Corbus Pharmaceuticals

About Corbus Pharmaceuticals

Corbus Pharmaceuticals

Corbus is committed to leveraging our expertise in immunology to fulfill our purpose of developing innovative new medicines that improve the lives of people living with inflammatory, fibrotic, and metabolic diseases, and cancer. Corbus’ current pipeline includes small molecules that activate or inhibit the endocannabinoid system and anti-integrin monoclonal antibodies that block activation of TGFβ.

Related Story

Appointments

 Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA | MTA

Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

March 7 2023

Corbus Pharmaceuticals, a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, […]

Appointments

 Corbus Pharmaceuticals Appoints Rachael Brake

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

December 7 2021

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced the appointment of Rachael Brake, […]